作者：李粉丽1 ，刘宏2 ，杜鹏1

单位：

1.671000云南省大理市，大理大学临床医学院　2.671000云南省大理市，大理大学第一附属医院心血管内科

单位（英文）：

1.School of Clinical Medicine, Dali University, Dali 671000, China 2.Department of Cardiology, the First Affiliated Hospital of Dali University, Dali 671000, China

关键词：

心力衰竭；钠-葡萄糖协同转运蛋白2抑制剂；肾素-血管紧张素-醛固酮系统；综述

关键词（英文）：

　Heart failure; Sodium-glucose cotransporter-2 inhibitors; Renin-angiotensin-aldosterone system; Review

中图分类号：

R 541.62

DOI：

10.12114/j.issn.1008-5971.2024.00.111

基金项目：

云南省教育厅科学研究基金项目（2023Y0975）

摘要：

近年来心力衰竭（HF）的发病率和再住院率仍呈上升趋势，而肾素-血管紧张素-醛固酮系统 （RAAS）过度激活在HF发病机制中扮演着重要角色。钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）为HF的新型治疗 药物，然而目前其临床获益的机制尚不完全明确。本文通过回顾相关文献，归纳了SGLT2i治疗HF的机制及其对患者 RAAS作用途径的影响，旨在为HF的临床治疗提供新思路。

英文摘要：

In recent years, the incidence rate and readmission rate of heart failure (HF) are still on the rise, and the overactivation of renin-angiotensin-aldosterone system (RAAS) plays an important role in the pathogenesis of HF. Sodium-glucose cotransporter-2 inhibitors are novel therapeutic agents for HF, but the mechanism of their clinical benefit is not completely clear at present. By reviewing relevant literature, this paper summarizes the mechanism of sodium-glucose cotransporter-2 inhibitors in the treatment of HF and their influence on the pathway of action of RAAS of patients, aiming to provide new ideas for the clinical treatment of HF.

参考文献：